Gunhild Keller

2.2k total citations · 1 hit paper
45 papers, 1.6k citations indexed

About

Gunhild Keller is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Gunhild Keller has authored 45 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 13 papers in Hematology and 12 papers in Molecular Biology. Recurrent topics in Gunhild Keller's work include Chronic Myeloid Leukemia Treatments (13 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Neuroendocrine Tumor Research Advances (8 papers). Gunhild Keller is often cited by papers focused on Chronic Myeloid Leukemia Treatments (13 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Neuroendocrine Tumor Research Advances (8 papers). Gunhild Keller collaborates with scholars based in Germany, United States and Italy. Gunhild Keller's co-authors include Gisela Zimmer, Eberhard Ritz, Kerstin Amann, Gerhard Mall, Andrew V. Schally, Gábor Halmos, J. Engel, Tim H. Brümmendorf, Attila Nagy and Artur Gontarewicz and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Gunhild Keller

44 papers receiving 1.6k citations

Hit Papers

Nephron Number in Patients with Primary Hypertension 2003 2026 2010 2018 2003 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gunhild Keller Germany 21 559 555 357 320 201 45 1.6k
Rachel Davis United States 13 206 0.4× 816 1.5× 520 1.5× 154 0.5× 35 0.2× 30 1.8k
Irma Isordia‐Salas Mexico 22 262 0.5× 262 0.5× 62 0.2× 330 1.0× 352 1.8× 81 1.4k
Ramin Radpour Switzerland 30 105 0.2× 1.3k 2.4× 595 1.7× 73 0.2× 322 1.6× 72 2.7k
Eddie Fridman Israel 27 137 0.2× 1.5k 2.6× 546 1.5× 209 0.7× 27 0.1× 74 3.0k
M Sorcini Italy 18 165 0.3× 826 1.5× 113 0.3× 49 0.2× 79 0.4× 47 1.4k
Jocelyn Wiggins United States 21 219 0.4× 1.1k 1.9× 119 0.3× 78 0.2× 79 0.4× 36 2.6k
Martin Pöhl Germany 23 167 0.3× 479 0.9× 261 0.7× 26 0.1× 89 0.4× 60 1.3k
Patricia Fernández‐Llama Spain 24 146 0.3× 1.3k 2.3× 135 0.4× 32 0.1× 250 1.2× 53 1.9k
Gustavo C. Rodriguez United States 29 93 0.2× 781 1.4× 733 2.1× 607 1.9× 48 0.2× 78 2.7k
Hiroyuki Kaneto Japan 15 116 0.2× 589 1.1× 261 0.7× 58 0.2× 25 0.1× 47 1.4k

Countries citing papers authored by Gunhild Keller

Since Specialization
Citations

This map shows the geographic impact of Gunhild Keller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gunhild Keller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gunhild Keller more than expected).

Fields of papers citing papers by Gunhild Keller

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gunhild Keller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gunhild Keller. The network helps show where Gunhild Keller may publish in the future.

Co-authorship network of co-authors of Gunhild Keller

This figure shows the co-authorship network connecting the top 25 collaborators of Gunhild Keller. A scholar is included among the top collaborators of Gunhild Keller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gunhild Keller. Gunhild Keller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Balabanov, Stefan, Thomas Wilhelm, Simone Venz, et al.. (2013). Combination of a Proteomics Approach and Reengineering of Meso Scale Network Models for Prediction of Mode-of-Action for Tyrosine Kinase Inhibitors. PLoS ONE. 8(1). e53668–e53668. 5 indexed citations
2.
Hennigs, Jan K., Gunhild Keller, Hans Jörg Baumann, et al.. (2011). Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?. BMC Pulmonary Medicine. 11(1). 30–30. 46 indexed citations
3.
Balabanov, Stefan, Artur Gontarewicz, Gunhild Keller, et al.. (2011). Abcg2 Overexpression Represents a Novel Mechanism for Acquired Resistance to the Multi-Kinase Inhibitor Danusertib in BCR-ABL-Positive Cells In Vitro. PLoS ONE. 6(4). e19164–e19164. 33 indexed citations
4.
Keller, Gunhild, Philippe Schafhausen, & Tim H. Brümmendorf. (2009). Bosutinib. Recent results in cancer research. 184. 119–127. 21 indexed citations
5.
Keller, Gunhild, Philippe Schafhausen, & Tim H. Brümmendorf. (2009). Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia. Expert Review of Hematology. 2(5). 489–497. 27 indexed citations
6.
Benten, Daniel, Gunhild Keller, Alexander Quaas, et al.. (2009). Aurora Kinase Inhibitor PHA-739358 Suppresses Growth of Hepatocellular Carcinoma In Vitro and in a Xenograft Mouse Model. Neoplasia. 11(9). 934–944. 56 indexed citations
7.
Keller, Gunhild, et al.. (2009). Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy. Hematological Oncology. 27(3). 123–129. 26 indexed citations
8.
Schrama, David, Gunhild Keller, Roland Houben, et al.. (2008). BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC. Journal of Carcinogenesis. 7(1). 1–1. 22 indexed citations
9.
Ugurel, Selma, David Schrama, Gunhild Keller, et al.. (2007). Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunology Immunotherapy. 57(5). 685–691. 58 indexed citations
10.
Keller, Gunhild, et al.. (2006). Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins. International Journal of Oncology. 28(6). 1507–13. 22 indexed citations
11.
13.
Engel, J., et al.. (2005). Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: Low induction of multidrug resistance proteins. European Journal of Cancer. 41(12). 1824–1830. 7 indexed citations
14.
Keller, Gunhild, Andrew V. Schally, Timo Gaiser, et al.. (2005). Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin’s lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. European Journal of Cancer. 41(14). 2196–2202. 21 indexed citations
16.
Engel, J., Gunhild Keller, Andrew V. Schally, et al.. (2005). Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone–releasing hormone analogues AN-152 and AN-207. Fertility and Sterility. 83(4). 1125–1133. 22 indexed citations
17.
Keller, Gunhild, Andrew V. Schally, Kate Groot, et al.. (2005). Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. Proceedings of the National Academy of Sciences. 102(30). 10628–10633. 18 indexed citations
18.
Dalderup, L. M., et al.. (1970). Serum lipids, typing, fibrinolysis, and smoking.. BMJ. 3(5716). 223.2–223. 5 indexed citations
19.
Keller, Gunhild, et al.. (1970). An investigation into the possible presence of nitrosamines in nitrite-bearing spinach. Food and Cosmetics Toxicology. 8(2). 167–171. 8 indexed citations
20.
Dalderup, L. M., et al.. (1969). A Practical Method for Decreasing the Serum Cholesterol Level in Man. American Journal of Clinical Nutrition. 22(11). 1521–1530. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026